November 16, 2011
Westlaw Journal
On December 7, 2011, The U.S. Supreme Court will hear arguments on the validity of two patents held by Prometheus Laboratories that cover abstract thoughts or processes in the field of biological sciences. The patents involve methods for calibrating the proper dosage of drugs to treat autoimmune diseases, according to filings before the high court. Finnegan partner Denise DeFranco said of the case, “Many patents in the life science space may be impacted by the decision…If the Supreme Court decides that Prometheus’ diagnostic patent claims are not patentable, then patents directed to methods of diagnosing and/or treating disease may be vulnerable to attack."
Commentary
May 20, 2026
Award/Ranking
Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award
May 13, 2026
Press Release
Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination
May 11, 2026
Award/Ranking
Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey
May 7, 2026
Announcement
Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International
May 4, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.